Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy.
暂无分享,去创建一个
Conor K McGarry | Mihaela Ghita | Kevin M Prise | G. Hanna | K. Butterworth | K. Prise | M. Ghita | C. McGarry | Karl T Butterworth | Gerard G Hanna | C. Taggart | Clifford C Taggart | Victoria Dunne | Donna M Small | Caroline B M Coffey | Sinead Weldon | Sarah O Osman | D. Small | S. Weldon | S. Osman | Victoria L. Dunne | C. B. Coffey | V. Dunne | Caroline B Coffey
[1] D. de Ruysscher,et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] K. Harrington,et al. The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[3] Isabel L Jackson,et al. Revisiting Strain-Related Differences in Radiation Sensitivity of the Mouse Lung: Recognizing and Avoiding the Confounding Effects of Pleural Effusions , 2010, Radiation research.
[4] E. Hammond,et al. Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] J. Nissink,et al. Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer. , 2015, Future medicinal chemistry.
[6] Borivoj Vojnovic,et al. SMALL ANIMAL IGRT SPECIAL FEATURE : COMMENTARY Implications of respiratory motion for small animal image-guided radiotherapy , 2016 .
[7] T. Conrads,et al. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo , 2015, Oncotarget.
[8] A. Ryan,et al. ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.
[9] B. Cornelissen,et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation , 2012, Cell Death and Disease.
[10] W. Mckenna,et al. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition , 2012, British Journal of Cancer.
[11] O. Fernandez-Capetillo,et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. , 2012, The Journal of clinical investigation.
[12] S. Bhide,et al. Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei , 2016, Molecular Cancer Therapeutics.
[13] Carlos Ortiz-de-Solorzano,et al. Longitudinal study of a mouse model of chronic pulmonary inflammation using breath hold gated micro-CT , 2010, European Radiology.
[14] Richard A. Adams,et al. Clinical development of new drug–radiotherapy combinations , 2016, Nature Reviews Clinical Oncology.
[15] S. Elledge,et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.
[16] J. Fowler,et al. Repair in mouse lung for up to 20 fractions of X rays or neutrons. , 1985, The British journal of radiology.
[17] M. Tomayko,et al. Determination of subcutaneous tumor size in athymic (nude) mice , 2004, Cancer Chemotherapy and Pharmacology.
[18] J. Fowler,et al. Repair in mouse lung of multifraction X rays and neutrons: extension to 40 fractions. , 1985, The British journal of radiology.
[19] M Oudkerk,et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Andrea Bezjak,et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.
[21] L. Karnitz,et al. Molecular Pathways: Targeting ATR in Cancer Therapy , 2015, Clinical Cancer Research.
[22] T. Puck,et al. ACTION OF X-RAYS ON MAMMALIAN CELLS , 1956, The Journal of experimental medicine.
[23] J. Masson,et al. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer , 2015, Biomolecules.
[24] Frank Verhaegen,et al. A longitudinal evaluation of partial lung irradiation in mice by using a dedicated image-guided small animal irradiator. , 2014, International journal of radiation oncology, biology, physics.
[25] Judith A. Goodship,et al. A splicing mutation affecting expression of ataxia–telangiectasia and Rad3–related protein (ATR) results in Seckel syndrome , 2003, Nature Genetics.
[26] A. Ashworth,et al. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment , 2012, Nature Reviews Clinical Oncology.
[27] K. Cimprich,et al. ATR: an essential regulator of genome integrity , 2008, Nature Reviews Molecular Cell Biology.
[28] H. Bolte,et al. Standardized quantification of pulmonary fibrosis in histological samples. , 2008, BioTechniques.
[29] J. Sarkaria,et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. , 1999, Cancer research.
[30] L. Zou,et al. DNA damage sensing by the ATM and ATR kinases. , 2013, Cold Spring Harbor perspectives in biology.
[31] M. Dewhirst,et al. Linking the History of Radiation Biology to the Hallmarks of Cancer , 2014, Radiation research.
[32] J. Bates,et al. Measuring the lung function in the mouse: the challenge of size , 2003, Respiratory research.
[33] C. Faivre-Finn,et al. The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).
[34] Nicolai J. Birkbak,et al. Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[35] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.